ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook Sells 250 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 250 shares of the stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $67.79, for a total transaction of $16,947.50. Following the sale, the vice president now directly owns 59,731 shares in the company, valued at $4,049,164.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Tuesday, February 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $56.04, for a total value of $14,010.00.

ANI Pharmaceuticals Stock Down 0.9 %

Shares of ANI Pharmaceuticals stock opened at $66.30 on Tuesday. The business has a fifty day simple moving average of $64.23 and a 200 day simple moving average of $58.42. The stock has a market cap of $1.40 billion, a PE ratio of 78.93 and a beta of 0.79. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. ANI Pharmaceuticals, Inc. has a 12 month low of $36.99 and a 12 month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. ANI Pharmaceuticals had a return on equity of 18.06% and a net margin of 3.86%. Research analysts predict that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on ANIP shares. Truist Financial boosted their target price on ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Capital One Financial initiated coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They set an “overweight” rating and a $80.00 price objective for the company. Guggenheim raised their target price on shares of ANI Pharmaceuticals from $70.00 to $77.00 and gave the company a “buy” rating in a research note on Tuesday, March 5th. Finally, HC Wainwright lifted their price target on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $80.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Rubric Capital Management LP boosted its position in shares of ANI Pharmaceuticals by 32.8% during the fourth quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock worth $62,032,000 after purchasing an additional 277,989 shares in the last quarter. Invesco Ltd. raised its stake in ANI Pharmaceuticals by 185.4% during the 3rd quarter. Invesco Ltd. now owns 339,735 shares of the specialty pharmaceutical company’s stock worth $19,725,000 after buying an additional 220,690 shares during the period. BlackRock Inc. lifted its holdings in ANI Pharmaceuticals by 9.9% during the second quarter. BlackRock Inc. now owns 2,133,100 shares of the specialty pharmaceutical company’s stock worth $114,825,000 after acquiring an additional 191,402 shares in the last quarter. Vanguard Group Inc. grew its stake in ANI Pharmaceuticals by 13.8% in the fourth quarter. Vanguard Group Inc. now owns 1,288,972 shares of the specialty pharmaceutical company’s stock valued at $71,074,000 after acquiring an additional 156,594 shares during the period. Finally, Balyasny Asset Management LLC bought a new stake in shares of ANI Pharmaceuticals in the third quarter worth about $4,466,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.